Singapore markets closed

Precigen, Inc. (PGEN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.45000.0000 (0.00%)
At close: 04:00PM EDT
1.4500 0.00 (0.00%)
After hours: 07:02PM EDT

Precigen, Inc.

20358 Seneca Meadows Parkway
Germantown, MD 20876
United States
301 556 9900
https://precigen.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees202

Key executives

NameTitlePayExercisedYear born
Mr. Randal J. Kirk J.D.Executive Chairman100kN/A1953
Dr. Helen Sabzevari Ph.D.President, CEO & Director1.29MN/A1962
Mr. Harry Thomasian Jr.Chief Financial Officer524.04kN/A1963
Mr. Rutul R. ShahChief Operating Officer393.54kN/A1981
Mr. Donald P. LehrChief Legal Officer & Corporate Secretary652.4kN/A1975
Mr. Jeffrey Thomas PerezSenior Vice President of Intellectual Property Affairs570.24kN/A1972
Mr. Steven HarasymVP & Head of Investor RelationsN/AN/AN/A
Mr. Rob RussellVP & Head of Human ResourcesN/AN/AN/A
Dr. Douglas E. Brough Ph.D.Senior VP & Head of ResearchN/AN/A1955
Dr. Bryan T. Butman Ph.D.Senior VP & Head of CMCN/AN/A1953
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Corporate governance

Precigen, Inc.’s ISS governance QualityScore as of 1 March 2024 is 5. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.